Filing Summary
Issuer discrepancy: The supplied filing is GlycoMimetics, Inc. (Nasdaq: GLYC), not Crescent BioPharma, Inc. It is a Form 10-K for the fiscal year ended December 31, 2020; the provided text does not give standalone fourth-quarter results.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. It had no approved products or product-sales revenue. Its lead candidate, uproleselan, was in a Phase 3 trial for relapsed or refractory acute myeloid leukemia (AML); GMI-1359 was in a Phase 1b trial, while GMI-1687 remained preclinical and in IND-enabling work.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $10.2 million | $0 |
| Research and development expense | $44.9 million | $47.0 million |
| General and administrative expense | $16.7 million | $14.4 million |
| Operating loss | $51.5 million | $61.4 million |
| Net loss | $51.0 million | $57.9 million |
| Net loss per share | $1.12 | $1.34 |
| Net cash used in operating activities | $39.2 million | $52.0 million |
| Cash and cash equivalents at year-end | $137.0 million | $158.2 million |
2020 revenue comprised payments under the Apollomics collaboration, including a $9.0 million upfront payment and a $1.0 million development milestone, plus clinical-supply revenue. No meaningful product revenue was reported. Gross margin is not presented as a meaningful measure for this development-stage business. The filing reports no borrowings; liabilities were primarily accrued expenses and operating lease obligations. Current assets were $138.3 million and current liabilities were $12.4 million at year-end. Remaining office lease obligations were approximately $3.1 million.
Material changes versus 2019
- Revenue increased from zero to $10.2 million, largely from the new Apollomics agreement licensing uproleselan and GMI-1687 in Greater China.
- Net loss narrowed by $6.9 million; operating expenses were nearly flat overall. R&D expense fell 4.5%, as lower manufacturing and formulation spending more than offset increased clinical-development costs.
- Operating cash use declined by $12.7 million, while cash decreased by $21.2 million during the year. Equity sales through at-the-market facilities generated $17.8 million net proceeds and increased shares outstanding.
- Pfizer terminated its rivipansel license effective April 2020 after the Phase 3 trial failed its primary and key secondary endpoints. GlycoMimetics regained the rights but said it would not pursue rivipansel for acute VOC.
Outlook, risks and unusual items
Management estimated existing cash would fund operating expenses and capital requirements into the fourth quarter of 2022, while cautioning that this estimate depends on assumptions and development timing. The company expected to complete enrollment in the uproleselan Phase 3 trial in the second half of 2021. That trial targeted approximately 380 patients; the separate NCI-sponsored study in newly diagnosed AML was expected to enroll approximately 670.
Key risks include clinical-trial failure or delays, continued operating losses and need for additional financing, dilution from equity issuance, dependence on third-party manufacturers and research organizations, competition, regulatory uncertainty, and the effects of COVID-19. COVID-related restrictions initially slowed trial site initiation and enrollment; management said enrollment had returned to forecasted rates but future effects remained uncertain. Apollomics could provide up to approximately $179 million in further development, regulatory and commercial milestones, plus tiered royalties, but these payments are contingent and uncertain. No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor’s report did not include an internal-controls attestation.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-K is GlycoMimetics, not Crescent BioPharma, and verify that this is the intended filing.
- Track uproleselan Phase 3 enrollment, timing, and eventual overall-survival results, as well as the NCI-sponsored trial’s progress.
- Assess cash burn, financing needs, dilution, and whether the stated cash runway remains achievable.
- Monitor Apollomics’ development progress and whether milestone or royalty conditions are met.
- Evaluate the implications of the failed rivipansel Phase 3 trial and the company’s decision not to continue it for acute VOC.